Daniela Rogoff, MD, Phd
- Vice President, Clinical Development
- QED Therapeutics
A subsidiary of BridgeBio, QED focuses on precision medicine for FGFR-driven cancers and conditions. We live by our name: QED, derived from the Latin “Quod Erat Demonstrandum” —Thus, It Has Been Proven.
Our business is inspired by our values –
PUT PATIENTS FIRST
BE RADICALLY TRANSPARENT
EVERY MINUTE COUNTS
LET SCIENCE SPEAK
What we do
With singular focus, QED is devoted to the development of our investigational candidate, infigratinib. A first-in-class, selective, tyrosine kinase inhibitor, infigratinib has promising early clinical data in patients with previously treated, FGFR-driven cholangiocarcinoma and metastatic urothelial carcinoma, as well as preclinical studies in achondroplasia. Future studies will investigate infigratinib for additional FGFR-driven tumor types and rare disorders.
Achondroplasia affects approximately 1 out every 20,000 newborns, and treatment advances for children with this bone growth disorder have been limited. Children with achondroplasia reach an adult height of 4 feet 10 inches or shorter and may also experience serious, often debilitating health complications. FGFR genetic alterations can cause more than 99% of achondroplasia cases.
Infigratinib for Achondroplasia
The latest information on the development of Infigratinib for patients with achondroplasia. Infigratinib is an orally bioavailable and selective FGFR1/2/3 selective tyrosine kinase inhibitor in development for FGFR-related conditions. Infigratinib in children with achondroplasia (ACH): design of PROPEL2 – a phase 2, open-label, dose-escalation and dose-expansion study